NEK4

Serine/threonine-protein kinase Nek4

26,889 patent compounds predicted against NEK4, 20,204 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL264158	0.79	3/20
SCHEMBL375534	0.54	3/20
SCHEMBL363119	0.44	3/20
SCHEMBL416549	0.40	3/20
SCHEMBL363116	0.39	3/20
SCHEMBL369534	0.39	3/20
SCHEMBL369535	0.39	3/20
SCHEMBL363842	0.37	3/20
SCHEMBL361993	0.37	3/20
SCHEMBL363521	0.36	3/20
SCHEMBL362642	0.36	3/20
SCHEMBL369687	0.36	3/20
SCHEMBL369688	0.36	3/20
SCHEMBL363855	0.35	3/20
SCHEMBL364346	0.35	3/20
SCHEMBL364544	0.34	3/20
SCHEMBL369613	0.34	3/20
SCHEMBL369614	0.34	3/20
Bi-2536 (SCHEMBL372489)	1.00	2/20
Bi-2536 (SCHEMBL614114)	1.00	2/20

Germline variants in NEK4 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full NEK4 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to NEK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	PHASE1	COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer	PHASE1	UNKNOWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	nan	RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK4 binder may also engage these)

Protein	Name	Similarity
Q9Z1J2	—	1.000	Q9Z1J2 →
F1M5M3	—	0.999	F1M5M3 →
Q5SW75	—	0.998	Q5SW75 →
Q9NYI0	—	0.997	Q9NYI0 →
Q6KAQ7	—	0.997	Q6KAQ7 →
Q3UIZ8	—	0.995	Q3UIZ8 →
Q94CU5	—	0.995	Q94CU5 →
Q5T7B8	—	0.995	Q5T7B8 →
A7MBB4	—	0.995	A7MBB4 →
Q69ZL1	—	0.995	Q69ZL1 →
A6X8Z5	—	0.994	A6X8Z5 →
F1MJR8	—	0.994	F1MJR8 →
Q2PFD7	—	0.994	Q2PFD7 →
P10244	—	0.994	P10244 →
Q949U2	—	0.994	Q949U2 →
Q86XD8	—	0.994	Q86XD8 →
Q6NTJ3	—	0.994	Q6NTJ3 →
Q76I76	—	0.994	Q76I76 →
Q6DFV7	—	0.994	Q6DFV7 →
Q8BLR5	—	0.994	Q8BLR5 →
Q9JIC3	—	0.994	Q9JIC3 →
Q76I79	—	0.994	Q76I79 →
Q811D2	—	0.993	Q811D2 →
A6QP06	—	0.993	A6QP06 →
A3KMW7	—	0.993	A3KMW7 →
Q498M5	—	0.993	Q498M5 →
Q5DW34	—	0.993	Q5DW34 →
Q569L8	—	0.993	Q569L8 →
PHF20	PHD finger protein 20	0.993	landscape →
Q8C0P0	—	0.993	Q8C0P0 →